Community-acquired pneumonia in adults
Conditions
Interventions
Four-day oral garenoxacin once daily after intravenous ampicillin/sulbactam once daily for 3 days
Four-day intravenous ampicillin/sulbactam once daily after intravenous Ampicillin/sulbactam once daily
Sponsors
Nagasaki evaluation organization for clinical interventions
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Adult patients with community-acquired pneumonia requiring hospitalisation and parenteral antibiotic therapy. 2) PSI II-IV 3) Patients after obtaining signed informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with episodes of aspiration 2) Patients with thoracic cavity drainage due to lung suppuration or empyema 3) Obstructive pneumonia due to airway obstruction 4) Legionella, MRSA, and P. aeruginosa are causative microorganism. 5) Patients who are treated with more than 10 mg of steroid 6) Patients with infections due to causative microorganism which is regarded as being ineffective to garenoxacin 7) Patients with a history of allergy/severe adverse effect to quinolone antibacterial agents or B-lactum antibacterial agents 8) Patients with a history of seizure/epilepsy or patients who are taking antiepilepsy drug 9) Patients with severe hepatic impairment, renal impairment, and cardiac impairment 10) Pregnancy/lactation 11) Patients who are regarded as inadequate subject by physician in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical and bacteriologic efficacy, chest radiograph resolution, and patient satisfaction in oral therapy and parenteral therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of the cost-effectiveness of oral therapy and parenteral therapy. | — |
Countries
Japan
Contacts
Public ContactKatsunori Yanagihara
Nagasaki University School of Medicine
Outcome results
None listed